Fouad Chebib
Mayo Clinic
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Fouad Chebib as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:23 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05190744 · Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium AdministrationMayo Clinic · completed · Autosomal Dominant Polycystic Kidney Disease, Nephrogenic Diabetes Insipidus, Acquired Nephrogenic Diabetes Insipidus · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:24 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Novel role of urinary urate in renal cystogenesis and water regulationR01DK142878 · NIDDK · MAYO CLINIC JACKSONVILLE · fiscal years 2025 · $2,967,657 awarded in 2025Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:24 UTC. The ranking covers the 200 most relevant of 1 PubMed records, and a shared surname and initials can bring in a namesake. All 1 on PubMed
- Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.Clin J Am Soc Nephrol · 201874 citationsRCR 3.3